MXiPr

Discovery

MXiPr first appeared on online research chemical markets in late 2020, without any prior description in pharmaceutical or academic literature. The National Forensic Laboratory of Slovenia performed the first formal laboratory identification in December 2020.^[2][3] Structurally, MXiPr is the N-isopropyl homolog of methoxetamine (MXE) — a minor modification to the nitrogen-attached alkyl chain that preserves the pharmacological core while producing a legally distinct molecule.

Forensic and pharmacological characterization

MXiPr emerged as part of a wave of MXE analogues — including MXPr and DMXE — designed to circumvent the scheduling of MXE across multiple jurisdictions.^[4][5] Tanaka et al. reported MXiPr in seized products in Japan, representing the first published forensic identification.^[2] Irie et al. subsequently published the only pharmacological characterization, measuring NMDA potency and flagging MXiPr as a "serious concern" given its potency and unregulated availability.^[1]

Market presence

MXiPr continues to circulate in European drug markets. A harm reduction drug-checking service in Marseille detected MXiPr in a submitted pill in October 2024.^[6] The French Addictovigilance Network has flagged the compound in the context of emerging ketamine analogue use patterns.^[10] Its detection in tablet form indicates it may be substituted for or combined with other substances in pressed pills, complicating identification for end users.

Structural class

MXiPr belongs to the arylcyclohexylamine chemical class — a family of compounds built around a cyclohexane ring bearing both an aromatic group and an amine nitrogen. This scaffold is shared with ketamine, phencyclidine (PCP), and methoxetamine (MXE). MXiPr is specifically a β-keto-arylcyclohexylamine, distinguished by a ketone group on the cyclohexane ring.

Within the MXE derivative series, MXiPr is the N-isopropyl homolog: the N-ethyl group of MXE is replaced with a branched isopropyl substituent. Closely related compounds include MXPr (N-propyl), DMXE (N-ethyl, lacking 3-methoxy), and deschloroketamine (DCK; N-methyl, lacking 3-methoxy).

Molecular identity

The molecular structure consists of a cyclohexanone ring bearing a 3-methoxyphenyl group and an isopropylamino substituent at the 2-position. The 3-methoxy group on the aromatic ring distinguishes MXiPr from deschloroketamine derivatives, while the N-isopropyl group differentiates it from MXE (N-ethyl) and MXPr (N-propyl). The compound is commercially available as the hydrochloride salt from analytical reference standard suppliers.

Stereochemistry

MXiPr possesses a chirality center at C2 of the cyclohexanone ring, producing two mirror-image enantiomers (R and S). Enantioseparation methods have been developed,^[11] but no data comparing the potency or safety of R- versus S-MXiPr have been published. For reference, S-ketamine is approximately twice as potent as R-ketamine at NMDA receptors;^[12] whether MXiPr exhibits comparable enantioselectivity is unknown.

Mechanism of action

MXiPr acts primarily as an NMDA receptor antagonist — it enters the open ion channel of the NMDA and blocks it in a use-dependent manner, the same mechanism established for ketamine and PCP.^[12][4] This blockade reduces glutamate-driven excitatory signaling, producing the characteristic dissociative state.

The only published measurement of MXiPr's receptor-level potency places it between MXE and DMXE in NMDA blocking strength.^[1] An in silico docking study confirmed the compound interacts within the NMDA receptor channel pore.^[1]

MXE has demonstrated affinity for the SERT (SERT)^[13] and sigma receptors,^[13] but whether MXiPr shares these secondary targets is unknown. The N-isopropyl substitution may alter binding at these sites relative to the N-ethyl parent. No published data exist for MXiPr at dopamine or norepinephrine transporters. inferred

Pharmacokinetics

No human pharmacokinetic studies have been published for MXiPr. Plasma half-life, bioavailability, and protein binding remain uncharacterized in humans.

The most detailed metabolic study examined MXiPr in rats and human liver microsomes.^[14] The primary metabolic pathways identified were N-dealkylation (loss of the isopropyl group, yielding the nor-metabolite), hydroxylation on the aromatic or cyclohexane ring, and phase II conjugation including glucuronidation. These metabolites enable targeted urinary detection of MXiPr use.^[14]

Arylcyclohexylamines are generally processed by the liver, as established for ketamine.^[12] Individuals with impaired liver function may experience prolonged drug exposure and increased toxicity risk. inferred

Where it acts

NMDA blockade by arylcyclohexylamines disrupts communication between the thalamus and cortex — the pathway responsible for integrating sensory information into coherent experience.^[12] At lower doses, this preferentially silences inhibitory interneurons, paradoxically increasing glutamate release in prefrontal regions and producing the stimulant-like lucidity reported at sub-dissociative levels.^[7] At higher doses, more complete NMDA blockade progressively disconnects the brain from sensory input, producing the immersive "hole" states described by users.

Why it matters

The predictive processing framework offers a unified account of dissociative phenomenology: by disrupting precision-weighted error signaling at NMDA synapses, these compounds degrade the brain's internal model of reality. At low doses, perception distorts and self-monitoring weakens; at high doses, the model collapses into complete sensory disconnection. Separately, ketamine research has demonstrated rapid formation of new neural connections following NMDA blockade — a mechanism underlying its antidepressant effects.^[12] Whether MXiPr produces comparable neuroplastic changes is unknown.

Toxicity

No controlled toxicity data exist for MXiPr. No lethal dose has been established in any species, and no human fatalities attributed solely to MXiPr appear in published literature. safety citation needed

Psychological risks

No published data characterize MXiPr's psychological risk profile specifically. Class-level risks for NMDA antagonists include anxiety, paranoia, and confusion during the acute phase — particularly at higher doses or in unfamiliar settings.^[16]

Dose-dependent impairment of working memory, decision-making, and spatial orientation occurs during and shortly after use. NMDA antagonists can trigger psychotic episodes in vulnerable individuals — the glutamate model of psychosis identifies NMDA blockade as a mechanism for both substance-induced and endogenous psychotic states.^[12]

Depersonalization and derealization are defining effects of the dissociative class, not adverse events per se, but may become distressing or persistent in susceptible individuals. The antidepressant-like properties observed for ketamine and MXE may attract self-medication use, creating patterns of escalating frequency.^[12]

Tolerance & dependence

No published studies characterize MXiPr-specific tolerance or dependence.

Tolerance develops with repeated use of NMDA antagonists as the brain compensates by increasing its glutamate signaling capacity. Cross-tolerance within the dissociative class — all NMDA antagonists — is expected.^[16] Community estimates place the functional tolerance half-life at approximately 5 days with full reset around 1.5 weeks. inferred

Physical dependence potential is moderate based on class inference from ketamine and MXE. Withdrawal from chronic NMDA antagonist use may involve anxiety, low mood, craving, and insomnia.

Psychological dependence potential is moderate. The warm, euphoric afterglow described in user reports,^[7] combined with the antidepressant-like properties of NMDA antagonists, suggests meaningful reinforcement potential. Compulsive redosing has been noted in community reports.

Drug interactions

No published drug interaction data exist for MXiPr. All assessments below are class-level inferences from the arylcyclohexylamine profile. inferred

CNS depressant combinations represent the highest-risk category. Additive depression of consciousness and breathing with opioids, benzodiazepines, alcohol, GHB, and barbiturates may be life-threatening. The fatal N-ethyldeschloroketamine case involved co-presence of morphine, oxycodone, and other compounds.^[8]

Serotonergic agent combinations carry potential risk if MXiPr shares the SERT affinity demonstrated for MXE.^[13] Combinations with MAOIs, SSRIs, or SNRIs could increase serotonin syndrome risk. The fatal case reported by Theofel et al. involved co-administration with venlafaxine (an SNRI).^[8]

Stimulant combinations may mask MXiPr's sedative effects at higher doses, increasing the risk of accidental overdose. Additive strain on the heart and circulation is a concern given the class-level increase in heart rate and blood pressure.

Other dissociative combinations produce unpredictable increases in dissociative intensity through additive NMDA receptor blockade. The interaction is hazardous in individuals without tolerance.

Contraindications

No substance-specific contraindication data exist for MXiPr. The following are inferred from the arylcyclohexylamine class profile. inferred

Absolute contraindications:

• History of psychotic disorders: NMDA antagonists can trigger or worsen psychotic episodes. Individuals with schizophrenia, schizoaffective disorder, or a personal history of psychosis should avoid all NMDA antagonists.
• Concurrent MAOI use: If MXiPr possesses serotonin transporter affinity (unconfirmed, inferred from MXE), combination with MAOIs poses serotonin syndrome risk.

Relative contraindications:

• Heart conditions: The sympathomimetic effects of NMDA antagonists (increased heart rate and blood pressure) pose elevated risk for individuals with pre-existing cardiovascular disease.
• Liver impairment: MXiPr undergoes extensive liver metabolism.^[14] Impaired liver function may prolong drug exposure and increase toxicity risk.
• Kidney or bladder conditions: Class-based concern for bladder and urinary tract damage, particularly with repeated use.
• Seizure disorders: User reports of seizures at high doses^[7] and the class-level seizure threshold effects^[16] indicate increased risk for individuals with epilepsy or lowered seizure threshold.
• Pregnancy and breastfeeding: No reproductive toxicity data exist. NMDA receptor signaling plays critical roles in brain development; exposure during pregnancy carries theoretical risk to the developing nervous system. safety citation needed

MXiPr occupies an ambiguous legal position in most jurisdictions. As a novel psychoactive substance that emerged in late 2020, it has been explicitly scheduled or prohibited in only a small number of countries. Its structural relationship to both ketamine (a controlled medicine) and PCP (a prohibited substance) creates variable legal exposure depending on how structural analog laws are interpreted.

The US federal status warrants particular caution. While MXiPr is not specifically scheduled, the Federal Analogue Act's applicability depends on prosecutorial interpretation of structural similarity. MXiPr's relationship to both ketamine (Schedule III, outside the Act's automatic trigger) and PCP (Schedule II, within its scope) creates legal ambiguity untested in court for this specific compound. Possession or distribution in the United States carries non-trivial legal risk despite the absence of explicit scheduling.